Table 1 Psoriasis cohort stratified by median MPO concentration

Age, y

50.90 ± 12.60

43.60 ± 12.10

0.07

Men, no. (%)

20 (100)

20 (100)

–

Framingham risk score

4.03 (1.24–5.58)

1.56 (0.25–7.76)

0.26

Race

15 (75)

14 (70)

> 0.99

Current smoker, no.

20 (100)

19 (95)

–

Hypertension, no.

18 (90)

17 (85)

0.66

BMI

25.55 (24.30–28.35)

26.05 (24.25–30.30)

0.55

Waist:hip ratio

0.99 (0.93–1.02)

0.96 (0.91–1.02)

–

Statin treatment, n (%)

0 (0)

0 (0)

–

PASI score

6.85 (2.40–11.45)

6.70 (5.05–14.05)

0.22

hsCRP, mg/L

1.80 ± 1.80

7.95 ± 11.70

0.08

GlycA, µmol/L

384.80 ± 48.80

440.36 ± 94.52

0.07

Neutrophils, K/µL

3.30 ± 1.16

4.28 ± 1.04

0.01

Monocytes, K/µL

0.50 ± 0.13

0.51 ± 0.13

0.11

Lymphocytes, K/µL

1.70 ± 0.55

1.73 ± 0.41

0.82

Neutrophil-lymphocyte ratio

2.0 ± 0.90

2.60 ± 0.90

0.09

Total cholesterol, mg/dL

187 ± 23.90

178.30 ± 39.50

0.41

LDL cholesterol, mg/dL

116.70 ± 27.16

111.30 ± 38.48

0.61

LDL particle number

1264.40 ± 299.54

1182.45 ± 416.35

0.48

LDL particle size

21.01 ± 0.63

20.93 ± 0.58

0.68

HDL cholesterol, mg/dL

52.6 ± 14.8

50.40 ± 10.80

0.60

HDL particle number

33.67 ± 5.80

31.68 ± 5.29

0.27

HDL particle size

9.02 ± 0.49

9.18 ± 0.49

0.25

HDL cholesterol efflux capacity

1.02 ± 0.20

0.89 ± 0.23

0.05

MPO concentration, ng/mL

58.80 (19.0–91.10)

187.8 (156.80–253.70)

< 0.001